Sitthichai Kesornsombat - Ginkgo Bioworks Executive Director, Director
| DNA Stock | USD 0.86 0.02 2.38% |
Director
Mr. Sitthichai Kesornsombat serves as Executive Director and Director of DNA 2002 PCL since 2008. He holds a Bachelors degree in Communications from Chulalongkorn University Thailand. since 2008.
| Age | 51 |
| Tenure | 16 years |
| Professional Marks | MBA |
| Address | 27 Drydock Avenue, Boston, MA, United States, 02210 |
| Phone | 877 422 5362 |
| Web | https://www.ginkgobioworks.com |
Ginkgo Bioworks Management Efficiency
The company has Return on Asset of (0.2182) % which means that on every $100 spent on assets, it lost $0.2182. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6302) %, meaning that it generated no profit with money invested by stockholders. Ginkgo Bioworks' management efficiency ratios could be used to measure how well Ginkgo Bioworks manages its routine affairs as well as how well it operates its assets and liabilities. As of May 2, 2024, Return On Tangible Assets is expected to decline to -0.61. In addition to that, Return On Capital Employed is expected to decline to -0.47. At present, Ginkgo Bioworks' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 107.1 M, whereas Net Tangible Assets are forecasted to decline to about 1.1 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Peter Wendell | Merck Company | 70 | |
| Robert Beech | LSI Industries | 64 | |
| Thomas Cech | Merck Company | 72 | |
| Paul Rothman | Merck Company | 63 | |
| Wendell Weeks | Merck Company | 59 | |
| John Morgan | LSI Industries | 63 | |
| Robert Kidder | Merck Company | 71 | |
| Dennis Meyer | LSI Industries | 80 | |
| Kathy Warden | Merck Company | 49 | |
| Wilfred OGara | LSI Industries | 60 | |
| Inge Thulin | Merck Company | 67 | |
| Craig Thompson | Merck Company | 64 | |
| William Harrison | Merck Company | 70 | |
| Thomas Glocer | Merck Company | 61 | |
| Leslie Brun | Merck Company | 68 | |
| Mark Serrianne | LSI Industries | 67 | |
| Amy Hanson | LSI Industries | N/A | |
| Christine Seidman | Merck Company | 68 | |
| Robert Steele | LSI Industries | 62 | |
| Rochelle Lazarus | Merck Company | 71 | |
| Gary Kreider | LSI Industries | 78 | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 |
Ginkgo Bioworks Holdings Leadership Team
Elected by the shareholders, the Ginkgo Bioworks' board of directors comprises two types of representatives: Ginkgo Bioworks inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ginkgo. The board's role is to monitor Ginkgo Bioworks' management team and ensure that shareholders' interests are well served. Ginkgo Bioworks' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ginkgo Bioworks' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna Wagner, Senior Development | ||
| Kenny Goh, CEO - Donaco Singapore, Deputy Group CFO | ||
| Samart Chuasiriphatthana, Managing Director, Executive Director, Director | ||
| Mark Dmytruk, Chief Officer | ||
| Suchet Sunthorawet, Director | ||
| Joshua Dunn, Head Design | ||
| Thomas Knight, Founder | ||
| Chun Na, Deputy Group CEO, CFO | ||
| Sirisak Piyathatsikun, Director | ||
| Austin Che, Head Founder | ||
| Benedict Reichel, Company Secretary, Executive Director | ||
| Kwong Chong, CFO | ||
| Steven CPA, Chief Officer | ||
| Paul Amatavivadhana, Director | ||
| Jason Kelly, CEO Founder | ||
| Robert Hines, Director | ||
| Suphakorn Chuasiriphatthana, Deputy Managing Director of Human Resources | ||
| Stuart McGregor, Non-Executive Chairman of the Board | ||
| Keong Lim, Group CEO, Managing Director, Executive Director | ||
| Bartholomew Canton, CTO Founder | ||
| Chathaphum Khantiwiriya, Director | ||
| Suphaphorn Chuasiriphatthana, Executive Director, Director | ||
| Ham Sukjaroenkraisri, Executive Director | ||
| Latthasanya Phiansompharn, Chairman of the Board | ||
| Samantha Sutton, Head People | ||
| Somkiat Chuasiriphatthana, Director | ||
| Att Asavanund, Deputy CEO | ||
| Reshma Shetty, President, Founder | ||
| Chaloemphong Mahawanitwong, Director | ||
| Sitthichai Kesornsombat, Executive Director, Director | ||
| Karen Tepichin, General Secretary | ||
| Marie Fallon, Chief Officer | ||
| Phongsakorn Phongsathaphorn, Company Secretary |
Ginkgo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ginkgo Bioworks a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (5.16) % | ||||
| Current Valuation | 1.08 B | ||||
| Shares Outstanding | 1.7 B | ||||
| Shares Owned By Insiders | 6.70 % | ||||
| Shares Owned By Institutions | 83.15 % | ||||
| Number Of Shares Shorted | 266.53 M | ||||
| Price To Earning | 25.51 X | ||||
| Price To Book | 1.98 X |
Ginkgo Bioworks Investors Sentiment
The influence of Ginkgo Bioworks' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Ginkgo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Ginkgo Bioworks' public news can be used to forecast risks associated with an investment in Ginkgo. The trend in average sentiment can be used to explain how an investor holding Ginkgo can time the market purely based on public headlines and social activities around Ginkgo Bioworks Holdings. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ginkgo Bioworks' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ginkgo Bioworks' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Ginkgo Bioworks' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Ginkgo Bioworks.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ginkgo Bioworks in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ginkgo Bioworks' short interest history, or implied volatility extrapolated from Ginkgo Bioworks options trading.
Pair Trading with Ginkgo Bioworks
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ginkgo Bioworks position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ginkgo Bioworks will appreciate offsetting losses from the drop in the long position's value.Moving together with Ginkgo Stock
| 0.81 | EVOK | Evoke Pharma | PairCorr |
Moving against Ginkgo Stock
| 0.66 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
| 0.61 | ELYM | Eliem Therapeutics Trending | PairCorr |
| 0.55 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.55 | HCWB | HCW Biologics | PairCorr |
| 0.53 | KRYS | Krystal Biotech Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Ginkgo Bioworks could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ginkgo Bioworks when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ginkgo Bioworks - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ginkgo Bioworks Holdings to buy it.
The correlation of Ginkgo Bioworks is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ginkgo Bioworks moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ginkgo Bioworks Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ginkgo Bioworks can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ginkgo Bioworks Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Ginkgo Stock analysis
When running Ginkgo Bioworks' price analysis, check to measure Ginkgo Bioworks' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ginkgo Bioworks is operating at the current time. Most of Ginkgo Bioworks' value examination focuses on studying past and present price action to predict the probability of Ginkgo Bioworks' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ginkgo Bioworks' price. Additionally, you may evaluate how the addition of Ginkgo Bioworks to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Ginkgo Bioworks' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.129 | Quarterly Revenue Growth (0.65) | Return On Assets (0.22) | Return On Equity (0.63) |
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.